• The Korean Journal of Nuclear Medicine Technology
• /
• v.18 no.2
• /
• pp.68-72
• /
• 2014

Purpose The nuclear medicine examination, there is a difficulty to carry out the inspection of both on the day of residual isotope due to the half-life. In this study, by studying the mutual influence and $^{18}F$-FDG of $^{99m}TcO_4{^-}$, I would like to explain the matters to be considered in the case of performing the same day. Materials and Methods With the NEMA-1994 Phantom, and experiments were performed 3 times. Create a 1: 4 Background ratio HOT and the $^{99m}TcO_4{^-}$ The first experiment: After underwent SPECT in INFINIA (GE Healthcare, MI, USA), and were injected with $^{18}F$-FDG 37 MBq in the Background area, 13 once for 60 minutes under the same conditions was time Scan. Create a 1: 4 Background ratio HOT and the $^{18}F$-FDG second is: The Scan in PET/CT Discovery 600 (GE Healthcare, MI, USA), and 148 MBq after injection $^{99m}TcO_4{^-}$ the Background area, once for 60 minutes, 6 under the same conditions was time Scan. Create a 1: 4 Background ratio HOT and the $^{18}F$-FDG experiments las, increments of 296 MBq and 148 MBq the 1 Bed Scan after $^{99m}TcO_4{^-}$, was 1 Bed Scan under the same conditions. Non BKG area and HOT, I was measured comparing the Total Counts and SNR or CNR. Results Showed a significant difference in the ratio CNR of enforcement during SPECT $^{18}F$-FDG is, (p>0.05). The $^{99m}TcO_4{^-}$ was no significant difference between the SNR ratio of PET / CT at the time of the effective date (p<0.05). I got the results $^{99m}TcO_4{^-}$ that reduce the Total Counts of PET / CT scan. Conclusion If you make a PET / CT scan, may affect the test using the $^{99m}TcO_4{^-}$ up to 12 hours, when it is performed before the $^{99m}TcO_4{^-}$, does not affect the SNR and SUV, PET / CT scan I reduced the detection efficiency. The inspection of day, we'd like to recommend a way to complement the detection efficiency to increase the inspection time of PET / CT in move forward the inspection using the $^{99m}TcO_4{^-}$.

• Nuclear Medicine and Molecular Imaging
• /
• v.42 no.3
• /
• pp.256-258
• /
• 2008

Osteopoikilosis is a rare, benign hereditary disease, which presents multiple osteosclerotic, and small round nodules in the bone. It is usually detected incidentally by radiological examination. A radionuclide bone scintigraphy is essential in distinguishing osteopoikilosis from osteoblastic metastases, because scintigraphic findings are usually normal in patients with osteopoikilosis. However, there have been no reports about F-18 fluorodeoxyglucose (FDG) PET findings in osteopoikilosis. Herein, we wish to report a case of osteopoikilosis with breast cancer, which could not be seen in either bone scintigraphy or F-18 FDG PET/CT.

• Journal of Biomedical Engineering Research
• /
• v.35 no.3
• /
• pp.68-74
• /
• 2014

Recent research on mild cognitive impairment (MCI) has shown that cognitive and memory decline in this disease is accompanied by disruptive changes in the brain functional network. However, there have been no graph-theoretical studies using $^{11}C$-PIB PET data of the Alzheimer's Disease or mild cognitive impairment. In this study, we acquired $^{18}F$-FDG PET and $^{11}C$-PIB PET images of twenty-four normal aging control participants and thirty individuals with MCI from ADNI (Alzheimer's Disease Neuroimaging Initiative) database. Brain networks were constructed by thresholding binary correlation matrices using graph theoretical approaches. Both normal control and MCI group showed small-world property in $^{11}C$-PIB PET images as well as $^{18}F$-FDG PET images. $^{11}C$-PIB PET images showed significant difference between NC (normal control) and MCI over large range of sparsity values. This result will enable us to further analyze the brain using established graph-theoretical approaches for $^{11}C$-PIB PET images.

• Nuclear Medicine and Molecular Imaging
• /
• v.43 no.6
• /
• pp.588-591
• /
• 2009

A 26-year-old man with renal cell carcinoma underwent $^{99m}Tc$-HDP bone scintigraphy for detecting bony metastasis after left total nephrectomy for renal cell carcinoma. $^{99m}Tc$-HDP bone scintigraphy showed small hot lesion in the first lumbar spine. About 12 months later, he underwent spinal MRI for lower back pain. A large mass was seen around spinous process of the first lumbar spine (L1) on spinal MRI and confirmed as metastatic renal cell carcinoma by bone biopsy. $^{99m}Tc$-HDP bone scintigraphy and $^{18}F$-FDG PET/CT were underwent for further evaluation. $^{99m}Tc$-HDP bone scintigraphy showed cold lesion in the first lumbar spine which was initially hot and newly developed hot lesion in the twelfth thoracic spine, and which were shown as hypermetabolic lesions in $^{18}F$-FDG PET/CT. We report a case of bony metastasis from renal cell carcinoma which is changed from hot lesion to cold lesion in $^{99m}Tc$-HDP bone scintigraphy and compare with $^{18}F$-FDG PET/CT.

• Nuclear Medicine and Molecular Imaging
• /
• v.42 no.5
• /
• pp.414-418
• /
• 2008

The role of positron emission tomography (PET) with F-18 fluorodeoxyglucose (F-18 FDG) in the diagnosis of hepatocellulcar carcinoma (HCC) has been limited because of a variable FDG uptake in HCC. However, the usefulness of PET/CT for detecting extrahepatic metastasis and monitoring of the treatment response in HCC has been reported. A 55-year-old man with a hepatitis B surface antigen-positive, was admitted to our hospital due to dyspnea, general weakness and body weight loss for one month. Chest X-ray showed multiple reticulo-nodular densities on both lower lung fields, which implies metastatic lesions. F-18 FDG PET/CT revealed consecutively intense hypermetabolic mass in right hepatic lobe, inferior vena cava and right atrium. We report a case of HCC with IVC and right atrium invasion identified by F-18 FDG PET/CT.

• The Korean Journal of Nuclear Medicine Technology
• /
• v.15 no.2
• /
• pp.26-29
• /
• 2011

Purpose: The general test method of the Korean Pharmacopeia specifies the test method on the clauses of quality control after manufacturing. According to KFDA Guidance for Medicines, standards of residual solvents regulates the maximum permissible dose of acetonitrile as 400 ppm, ethanol as 5,000 ppm, and acetic acid as 5,000 ppm. This study aims at identifying the type of resiual solvents in the final [F-18]FDG vial of an automatic synthesizer and measure its residual quantity. Materials and Methods: The center carried out residual solvents test of [F-18]FDG injection using Agilent Technologies 7890A with a Flame Ionization Detector. The column of Agilent Technologies 7890A used in measuring of residual solvents was CP WAX column ($30m{\times}0.53mm{\times}1.0{\mu}m$) and analysis condition was split mode 1:1 at the initial temperature $70^{\circ}C$ which was increased $20^{\circ}C/minute$ after two minutes and maintained at the final $140^{\circ}C$ for two minutes. The analysis method was as following: Firstly, ethanol-acetonitrile-acetic acid mixture was classified into four types of concentration (250-25-250 ppm, 1,000-100-1,000 ppm, 3,000-300-3,000 ppm, and 6,000-600-6,000 ppm), and $1.0{\mu}L$ of each type of concentration was injected into gas chromatography followed by an analysis of its peak domain. Then, a calibration-curve by the external standard method was drawn based on the analysis result. Results: While ethanol and acetonitrile were detected in TRACERlab MX, FASTlab had additional acetic acid. The residual quantity of the ethanol-acetonitrile-acetic acid mixture evaluated using the calibration-curve was average 72 ppm ethanol, 54 ppm acetonitrile, and 1030 ppm acetic acid for FASTlab, whereas average 439 ppm ethanol and 79 ppm acetonitrile for TRACERlab MX. This indicated that both of them were within the maximum permissible dose. Conclusion: Solvent residues in the [F-18]FDG injection were all within maximum permissible doses and proper to be used to examine a patient. The result indicated that types and quantities of solvent resides of radioactive pharmaceuticals vary depending on the automatic synthesizer.

• The Korean Journal of Nuclear Medicine Technology
• /
• v.15 no.2
• /
• pp.36-40
• /
• 2011

Purpose: $^{18}F$-FDG injected dose to the patient is quite different between the recommended dose from manufacturer and the actual dose applied to each of hospitals. injection of inappropriate $^{18}F$-FDG dose may not only increase the exposed dose to patients but also reduce the image quality. we thus evaluated the proper $^{18}F$-FDG injected dose to decrease the exposed dose to patients considering the image quality. Materials And Methods: NEMA Nu2-1994 phantom was filled with $^{18}F$-FDG increasing hot cylinder radioactivity concentration to 1, 3, 5, 7, 9 MBq/kg based on the ratio of 4:1 between the hot cylinder and background activity. after completing the transmission scan using ct, emission scan was acquired in 3D mode for 2 minutes 30 seconds/bed. ROI was set up on hot cylinder and background radioactivity region. after measuring $SUV_{max}$ those regions, then analyzed SNR at the points. clinical experiment has been conducted the object of patients who have came to smc from november 2009 to august 2010, 97 patients without having a hepatic lesions were selected. ROI was set up in the liver and thigh area. after measuring $SUV_{max}$, the image quality was compared following the injected dose. Results: in phantom study, as the injected radioactivity concentration per unit mass was 1, 3, 5, 7, 9 MBq/kg, $SUV_{max}$ was 23.1, 24.1, 24.3, 22.8, 23.6 and SNR was shown 0.48, 0.54, 0.56, 0.55, 0.55. according to increment of the injected dose, $SUV_{max}$ and SNR was increased under 5 MBq/kg but they were decreased over 7 MBq/kg. in case of clinical experiment, as increased the injected radioactivity concentration per unit mass was 4.72, 5.34, 6.16, 7.41, 8.68 MBq/kg, $SUV_{max}$ was 2.68, 2.67, 2.26, 1.88, 1.95 and SNR was shown 0.52, 0.53, 0.46, 0.46, 0.44. if the injected dose exceeds 5 MBq/kg, showed a decrease pattern as phantom study. Conclusion: increasing $^{18}F$-FDG injected dose considered patient's body weight improve image quality within a certain range. if it exceeds the range, it can be reduced image quality due to random and scatter coincidences. this study indicates that the optimal injected dose was 5 MBq/kg per unit mass the injected radioactivity concentration in 3d wb pet/ct.

• Nuclear Medicine and Molecular Imaging
• /
• v.42 no.sup1
• /
• pp.101-109
• /
• 2008

Cervix cancer is one of common gynecological cancers in the world, and staged with FIGO or TNM system. However, these clinical staging systems lack information about lymph node or distant metastases, thus imaging modalities are considered to make an appropriate therapeutic plan and enhance overall survival rate. In this context, FDG PET is recommended to pre-treatment stating and prognosis prediction, for it could noninvasively evaluate the status of lymph nodes, especially abdominal paraaortic nodes which are closely related with prognosis. Moreover, the degree of FDG uptake is correlated with prognosis. Although there is no consistent method for surveillance of cervix cancer, FDG PET seems a very important tool in detecting tumor recurrence because it is much more advantageous than conventional imaging modalities such as MRI for discerning recurrent tumor from fibrosis caused by radiation or surgery. Furthermore, FDG PET could be used to evaluate treatment response. On the other hand, recently introduced PET/CT is expected to play an ancillary role to FIGO staging by adding anatomical information, and enhance diagnostic performance of PET by decreasing false positive findings.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.1 no.2
• /
• pp.123-129
• /
• 2015

$^{64}Cu$-labeled diacetyl-bis($N^4$-methylthiosemicarbazone) is a promising agent for internal radiation therapy and imaging of hypoxic tissues. In the study, we confirmed hypoxia regions in VX2 tumor implanted rabbits with injection $^{64}Cu$-ATSM and $^{18}F$-FDG using positron emission tomography (PET)/computed tomography (CT). PET images with $^{18}F$-FDG and $^{64}Cu$-ATSM were obtained for 40 min by dynamic scan and additional delayed PET images of $^{64}Cu$-ATSM the acquired up to 48 hours. Correlation between intratumoral $O_2$ level and $^{64}Cu$-ATSM PET image was analyzed. $^{64}Cu$-ATSM and $^{18}F$-FDG were intravenously co-injected and the tumor was dissected and cut into slices for a dual-tracer autoradiographic analysis. In the PET imaging, $^{64}Cu$-ATSM in VX2 tumors displayed a specific uptake in hypoxic region for48 h. The uptake pattern of $^{64}Cu$-ATSM in VX2 tumor at 24 and 48 h did not match to the $^{18}F$-FDG. Through ROI analysis, in the early phase (dynamic scan), $^{18}F$-FDG has positive correlation with $^{64}Cu$-ATSM but late phase (24 and 48 h) of the $^{64}Cu$-ATSM showed negative correlation with $^{18}F$-FDG. High uptake of $^{64}Cu$-ATSM in hypoxic region was responded with significant decrease of oxygen pressure, which confirmed by $^{64}Cu$-ATSM PET imaging and autoradiographic analysis. In conclusion, $^{64}Cu$-ATSM can utilize for specific targeting of hypoxic region in tumor, and discrimination between necrotic- and viable hypoxic tissue.

• The Korean Journal of Nuclear Medicine
• /
• v.36 no.1
• /
• pp.19-27
• /
• 2002

The annual incidence of primary brain tumors is 7-19 cases per 100,000 people. The unique capacity of visualizing biochemical processes allows PET to determine functional metabolic activities of the brain tumors. Like other malignant tumors, F-18 FDG has been used commonly in the imaging of brain tumors. FDG PET is valuable in grading malignancy, predicting prognosis, monitoring treatment, differentiating tumor recurrence from radiation necrosis, and detecting primary lesion in metastatric brain tumors. Among amino acids labeled with positron emitters, C-11 methionine is used clinically. Tumor delineation is much better with methionine PET than with FDG PET. Low grade gliomas, in particular, are better evaluated with methionine than with FDG. PET opens another dimension in brain tumor imaging. PET imaging has clearly entered the clinical area with a profound impact on patient care in many indications.